Treating the Disease or Opening a Learning Window? What a New Review of Psychedelics for Substance Use Disorders Means for Canadian Practitioners

Substance use disorders remain one of the hardest problems in mental health care, and one where psychedelic research has drawn intense interest. A review published on October 29, 2026 in the journal Brain Sciences asks a question that practitioners will recognize: when a psychedelic appears to help someone with an addiction, is the drug treating the disease, or is it opening a temporary window in which treatment, learning and recovery work differently?

The review was written by Adela G. Buciuc and Brian Fuehrlein of the Department of Psychiatry at Yale University School of Medicine, together with Mark S. Gold of Washington University School of Medicine in St. Louis, and it appears in a special issue on new classes of treatment emerging in addiction and psychiatry. It is a synthesis of existing evidence rather than a new trial, so its value lies in how it organizes what is known and where it draws the line between promise and proof.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

What the review argues

The authors start from a sober assessment of current care. In their framing, existing treatment for substance use disorders is "better described as disease management than as cure." Medications for opioid, alcohol and tobacco use disorders reduce use, and opioid agonist treatment reduces mortality, but retention in treatment is poor and functional recovery is rarely measured.

Against that backdrop, the review evaluates each psychedelic and psychedelic-inspired compound on its own terms, tracing cellular mechanisms, animal findings and human trials across different substance use disorders. Its central methodological point is that "relapse prevention" is not one thing. Conditioned place preference, operant reinstatement, extinction learning and clinical abstinence each capture a different process, and in the authors' words, "agreement at one level does not imply agreement at another." A compound that looks convincing in an animal model of reinstatement may say little about whether a patient stays abstinent at six months.

From that analysis the authors conclude that translational support is "indication- and compound-specific rather than a class property." In plain terms: evidence for one psychedelic in one disorder does not transfer to another psychedelic, or even to the same psychedelic in a different disorder.

Where the human evidence stands, compound by compound

According to the abstract, the strongest human signals are for psilocybin in tobacco and alcohol use disorders. Even there, the authors are careful: the alcohol signal "rests on two small randomized trials with discordant results." That is a notably restrained reading of a body of evidence that is often described more confidently in public discussion.

Ibogaine, which has attracted attention for opioid use disorder, is described as "gated by cardiotoxicity." Ketamine, already in clinical use in Canada for depression, "carries reinforcing properties and organ toxicity of its own," a reminder that a compound's abuse liability belongs in any conversation about using it to treat addiction. The review also lists 5-MeO-DMT and non-hallucinogenic psychedelic-inspired compounds among the agents it considers.

The paper's closing line captures its stance: "Plasticity is an opportunity, not an outcome."

Why the "learning window" framing matters for practitioners

For nurses, physicians, psychologists and therapists in Canada, the most useful idea in the review is not any single trial result but the reframing itself. If a psychedelic session produces a period of heightened plasticity in which learning and recovery work differently, then what happens in and around that period, including preparation, the therapeutic relationship, integration sessions and the behavioural treatment that follows, becomes the active ingredient rather than an add-on.

That view aligns with how psychedelic-assisted therapy is structured in clinical trials, where dosing sessions sit inside a course of psychotherapy, and it offers a clear argument for why practitioner skill is not optional. A window is only useful if someone is trained to work within it. It also sets expectations appropriately for patients: a single session is not a cure, and the review's own language cautions against treating it as one.

The compound-by-compound safety points carry practical weight too. The cardiotoxicity concern with ibogaine mirrors the detailed screening and monitoring questions that regulators have recently raised; the U.S. FDA is currently collecting public comment on early-phase ibogaine trial design under docket FDA-2026-N-10429, with comments closing November 20, 2026. Ketamine's reinforcing properties argue for careful patient selection and follow-up in any ketamine-assisted protocol, particularly for people with a history of substance use.

The Canadian context

In Canada, psychedelic-assisted therapy for substance use disorders remains confined to clinical trials and, in limited cases, Health Canada's case-by-case authorization initiated by a physician, while ketamine-assisted therapy is available through licensed clinics under physician oversight. That makes the review's emphasis on indication-specific evidence especially relevant: Canadian practitioners are likely to field questions from patients who have read about psilocybin for alcohol use or ibogaine for opioid use, and being able to explain the difference between a promising signal and an established treatment is itself a clinical skill.

The review does not settle whether psychedelics treat the disease or open a learning window. What it does is give practitioners a disciplined vocabulary for discussing the evidence, and a reason to invest in the parts of care that happen when the drug has worn off.

Building the skills to work inside the window

ATMA CENA's Advanced Pathways are complete training programs that include the Psychedelic Therapy Foundations course as part one and progress into the preparation, session-support and integration skills that this review implicitly calls for. Most courses are delivered online; the KAT Immersive is offered in person in Calgary. If you would like to talk through which pathway fits your scope of practice, you can book a program-advisor call or explore the options on the psychedelic therapy training page.

Sources

1. Psychedelics and Psychedelic-Inspired Compounds for Substance Use Disorders: Are We Treating the Disease or Opening a Learning Window?. Brain Sciences, 16(11), 2026.
2. Weekly Psychedelic Policy Briefing: Oct. 27, 2026. Psychedelics Today, 2026.